[go: up one dir, main page]

WO2000009754A3 - HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS - Google Patents

HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS Download PDF

Info

Publication number
WO2000009754A3
WO2000009754A3 PCT/US1999/018387 US9918387W WO0009754A3 WO 2000009754 A3 WO2000009754 A3 WO 2000009754A3 US 9918387 W US9918387 W US 9918387W WO 0009754 A3 WO0009754 A3 WO 0009754A3
Authority
WO
WIPO (PCT)
Prior art keywords
coa desaturase
stearoyl
human
methods
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/018387
Other languages
French (fr)
Other versions
WO2000009754A2 (en
Inventor
Kurt Stenn
Stephen M Prouty
Satish Parimoo
Lin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
Johnson and Johnson Consumer Companies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Consumer Companies LLC filed Critical Johnson and Johnson Consumer Companies LLC
Priority to EP99945051A priority Critical patent/EP1105538A2/en
Priority to JP2000565188A priority patent/JP2003533965A/en
Priority to CA002339748A priority patent/CA2339748A1/en
Priority to AU57746/99A priority patent/AU5774699A/en
Publication of WO2000009754A2 publication Critical patent/WO2000009754A2/en
Publication of WO2000009754A3 publication Critical patent/WO2000009754A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention provides a nucleic acid molecule encoding human stearoyl-CoA desaturase, and isolated protein encoded thereby. This invention also provides a method of diagnosing a human subject for a skin disorder characterized by an abnormal level of stearoyl-CoA desaturase expression. This invention further provides a method for determining whether an agent increases the expression level of human stearoyl-CoA desaturase in skin cells already expressing same. This invention further provides methods for determining whether an agent increases or decreases the expression level or activity of human stearoyl-CoA desaturase in skin cells already expressing same. This invention still further provides pharmaceutical compositions for treating human skin disorders characterized by abnormal stearoyl-CoA desaturase expression and/or activity, and related methods of treatment. Finally, this invention provides related antibodies, gene therapy vectors, and transgenic mice.
PCT/US1999/018387 1998-08-14 1999-08-12 HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS Ceased WO2000009754A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99945051A EP1105538A2 (en) 1998-08-14 1999-08-12 HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
JP2000565188A JP2003533965A (en) 1998-08-14 1999-08-12 Human stearoyl-CoA desaturase-related compositions and methods for treating abnormal skin conditions
CA002339748A CA2339748A1 (en) 1998-08-14 1999-08-12 Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
AU57746/99A AU5774699A (en) 1998-08-14 1999-08-12 Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9652098P 1998-08-14 1998-08-14
US60/096,520 1998-08-14

Publications (2)

Publication Number Publication Date
WO2000009754A2 WO2000009754A2 (en) 2000-02-24
WO2000009754A3 true WO2000009754A3 (en) 2000-08-24

Family

ID=22257742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018387 Ceased WO2000009754A2 (en) 1998-08-14 1999-08-12 HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS

Country Status (4)

Country Link
AR (1) AR020190A1 (en)
AU (1) AU5774699A (en)
CO (1) CO5280032A1 (en)
WO (1) WO2000009754A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19955349A1 (en) * 1999-11-17 2001-08-02 Switch Biotech Ag Use of novel polypeptide or its variant or nucleic acid encoding the polypeptide for diagnosing and/or preventing and/or treating skin disorders and/or treatment in wound healing or for identifying active substances
AU4722801A (en) 2000-02-24 2001-09-03 Xenon Genetics Inc Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
US6686185B1 (en) 2000-03-07 2004-02-03 Millennium Pharmaceuticals, Inc. 25934, a novel fatty acid desaturase and uses therefor
AU2001289457A1 (en) 2000-09-26 2002-04-08 Xenon Genetics Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
WO2002040666A2 (en) * 2000-11-17 2002-05-23 Xenon Genetics Inc. Fat regulated genes, uses thereof, and compounds for modulating same
US7132529B2 (en) 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050043256A1 (en) 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US6759208B2 (en) 2001-08-29 2004-07-06 Xenon Genetics Inc. High throughput screening assays using fatty acid synthetic enzymes
WO2003083047A2 (en) 2002-03-01 2003-10-09 Exelixis, Inc. MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003294446A1 (en) * 2002-11-21 2004-06-18 Bayer Pharmaceuticals Corporation Regulation of stearoyl-coa desaturase to treat obesity
FR2853910B1 (en) * 2003-04-16 2007-08-24 Galderma Res & Dev GENES OF PSORIASIS
US7759348B2 (en) * 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2011156136A1 (en) 2010-06-11 2011-12-15 Avon Products, Inc. Use of eclipta prostrata and other ppar-gamma inhibitors in cosmetics and compositions thereof
RU2634862C2 (en) 2011-05-19 2017-11-07 Торэй Индастриз, Инк. Immunity-inducing agent
CN108699589B (en) * 2016-07-08 2021-08-13 花王株式会社 Preparation method of nucleic acid sample
WO2021182568A1 (en) * 2020-03-11 2021-09-16 花王株式会社 Method for preparing rna derived from skin surface lipids

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 1997, AL JERYAN L ET AL.: "Characterization and expression of a stearoyl CoA desaturase from human liver", XP002139045 *
KAESTNER K H ET AL.: "Differentiation-induced gene expression in 3T3-L1 preadipocytes", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 25, 1989, pages 14755 - 14761, XP002139043 *
LI J ET AL.: "Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues", INTERNATIONAL JOURNAL OF CANCER, vol. 57, 1994, pages 348 - 352, XP000910652 *
MILLER C W AND NTAMBI J M: "Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase I gene expression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 93, 1996, pages 9443 - 9448, XP002139044 *
NTAMBI J M ET AL.: "A model cell line to study regulation of stearoyl-CoA desaturase gene 1 expression by insulin and polyunsaturated fatty acids", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 220, 1996, pages 990 - 995, XP002139042 *
PARIMOO S ET AL.: "Identification of a novel SCD gene and expression of the SCD family in mouse skin", JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, vol. 4, 1999, pages 320 - 322, XP000911022 *
ZHANG L ET AL.: "Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites", BIOCHEMICAL JOURNAL, vol. 340, 1999, pages 255 - 264, XP000913556 *

Also Published As

Publication number Publication date
AR020190A1 (en) 2002-05-02
CO5280032A1 (en) 2003-05-30
AU5774699A (en) 2000-03-06
WO2000009754A2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
ATE464391T1 (en) HYALURONIDASE FROM HUMAN PLASMA
WO1999055564A8 (en) Materials and methods for gene therapy
WO2001036432A3 (en) 18 human secreted proteins
WO2001034768A3 (en) 15 human secreted proteins
WO2001012776A3 (en) 18 human secreted proteins
AU2001282364A1 (en) Diagnosis and treatment of prostate cancer
WO2000052136A3 (en) Human glycosylation enzymes
WO2000077026A8 (en) 49 human secreted proteins
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO1999062561A3 (en) Gene therapy method
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2001016334A3 (en) Human hydrolytic enzymes
WO2000063230A3 (en) 49 human secreted proteins
MXPA02000293A (en) Cyclic amp phosphodiesterase isoforms and methods of use.
WO2000070047A3 (en) Full-length molecules expressed in human tissues
WO2001012775A3 (en) 25 human secreted proteins
WO2000058339A3 (en) 50 human secreted proteins
HK1047113A1 (en) A DNA MOLECULE ENCODING A VARIANT α2B-ADRENOCEPTOR PROTEIN, AND USES THEREOF
WO2000061624A8 (en) 48 human secreted proteins
WO2000043495A3 (en) 33 human secreted proteins
WO1998059041A3 (en) Disease related nucleotide kinases
WO2001083524A3 (en) Rna metabolism proteins
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2339748

Country of ref document: CA

Ref country code: CA

Ref document number: 2339748

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999945051

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999945051

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999945051

Country of ref document: EP